Regulatory b cells and their uses
US-2016375059-A1 · Dec 29, 2016 · US
US9528088B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9528088-B2 |
| Application number | US-201314086841-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2013 |
| Priority date | Jun 28, 2002 |
| Publication date | Dec 27, 2016 |
| Grant date | Dec 27, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.
Opening claim text (preview).
What is claimed is: 1. A method for activating and expanding naïve T cells present in a mixed population of T cells comprising naïve T cells and antigen-specific memory T cells, the method comprising: contacting the mixed population of T cells with a surface having attached thereto agents with binding activity to cell surface moieties on the surfaces of T cells in the mixed population, thereby (a) expanding naïve T cells, and (b) deleting antigen-specific memory T cells present in the mixed population of T cells, wherein the agents having binding affinity for CD3 protein complexes and CD28 proteins, and wherein the ratio of surface to cells is at least 5:1. 2. The method of claim 1 , wherein one or both of the agents are antibodies or an antibody fragments. 3. The method of claim 1 , wherein one of the agents is an anti-CD3 antibody or an anti-CD3 antibody fragment. 4. The method of claim 1 , wherein one of the agents is an anti-CD28 antibody or an anti-CD28 antibody fragment. 5. The method of claim 1 , wherein an anti-CD3 antibody or an anti-CD3 antibody fragment and an anti-CD28 antibody or an anti-CD28 antibody fragment are co-localized on the same surface. 6. The method of claim 1 , wherein the ratio of surface to cells is between 5:1 and 10:1.
Drugs for immunological or allergic disorders · CPC title
Regulators of apoptosis · CPC title
Purging against subsets of blood cells, e.g. purging alloreactive T cells · CPC title
T cells · CPC title
Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.